Find us on:

Two-day summit of specialists in fibromyalgia and chronic fatigue syndrome concludes: LDN is the top choice for treatment of chronic pain in these patients.

In a recent story, Medscape News Reporter Miriam E. Tucker shares new insights into LDN’s use for treatment of chronic pain conditions.

University of Alabama’s Neuroinflammation, Pain and Fatigue Lab’s director, Jarred W. Younger (PhD), believes that LDN could be good news for patients of chronic pain in the form of an affordable alternative to the conventionally available opioid. Usage of LDN could prove to be positively life changing for patients of conditions such as ME/CFS and Fibromyalgia.

Usage of LDN could prove to be positively life changing for patients of conditions such as ME/CFS and Fibromyalgia.

Stay Empowered! Subscribe Now for News Alerts

There is a need for further studies to reach any final conclusions but the current findings are promising. When compared to other opioids, LDN shows much better long-term results due to the fact that it does not cause pain sensitivity like most opioids do. On the contrary, it reduces sensitivity to pain over the course of time according to Jarred W. Younger.

LDN’s anti-inflammatory actions have also gained attention in the recent years. The fact that only one tenth of naltrexone’s dosage for treating opioid dependence will be able to treat chronic pain makes LDN the next most potential solution to the problem. LDN has shown pain reducing effects in various conditions that result in inflammation of various body organs such as multiple sclerosis and IBD (inflammatory bowel disease).

LDN has been working, and the proof of its success at treating chronic pain lies in the statements that come from the doctors who specialize in the treatment of conditions like ME/CFS and Fibromyalgia. LDN was the top choice of 13 clinicians at a 2-day summit in Salt Lake City at the Bateman-Horne Center for treating chronic pain in people suffering from Myalgic Encephalopathy. They gave their verdict in the favor of LDN after treating many patients with the drug and observing the results.

LDN was the top choice of 13 clinicians at a 2-day summit in Salt Lake City at the Bateman-Horne Center for treating chronic pain in people suffering from Myalgic Encephalopathy.

The Bateman-Horne Center director, Dr. Lucinda Bateman, agrees that her use of LDN on patients with chronic pain has yielded great results. She concludes from her experience that LDN is as effective as other drugs used for treating fibromyalgia. The additional benefit, however, is that it costs much less than those drugs.

To watch and listen to Dr. Bateman’s summary of the summit, visit: https://www.youtube.com/watch?v=2w-06T9oAZ8

Source: Medscape News (free registration)